Portfolio news 0

• The Times top Tech100 growth company becomes part of the UK innovation ecosystem with membership to the Knowledge Quarter
• Genomics invites partners to explore the powerful new agentic AI capabilities on Mystra drug discovery platform

25th February 2026. Genomics, the science-led techbio company today opens its new flagship London Office in the Knowledge Quarter, officially inaugurated by Dr Zubir Ahmed, Minister for Health and Life Sciences.  The company will also confirm its formal membership of the Knowledge Quarter community and unveil new agentic AI capabilities within its Mystra drug discovery platform. 

The new office places Genomics at the heart of one of the world’s most concentrated clusters of scientific, academic and clinical excellence alongside leading research institutes, NHS partners and life sciences organisations. Membership of the Knowledge Quarter further strengthens the company’s commitment to collaboration across the UK innovation ecosystem. 

The London expansion marks a significant milestone in Genomics’ growth, reflecting increasing demand from pharmaceutical and biotech partners for advanced genomic analytics and AI-enabled target discovery. Over the past decade, Genomics has been applying and evolving its proprietary scientific analytics methods to large-scale genetic association datasets to accelerate innovation across life sciences and healthcare. The company’s Mystra SaaS platform is built on infrastructure hosted by partner, Amazon Web Services.

Dr Zubir Ahmed, Minister for Health and Life Sciences, said: “As a practising surgeon, I know just how crucial it is to harness medical breakthroughs, so patients get the latest and most advanced treatments quickly and safely. This opening shows how the Life Sciences Sector Plan is giving confidence to medical innovators to deliver, scale and grow in Britain - driving our economy and benefitting patients. By combining the care of the NHS with the ingenuity of our scientists, our health service can truly become the envy of the world once again.”

At the event, Genomics will unveil new agentic AI capabilities integrated into its Mystra platform. These will serve as a force multiplier, enabling today’s core users to work more effectively and efficiently, but will also democratise insight generation to a much broader group of stakeholder types across the research and development spectrum, allowing users to:

• Accelerate identification and validation of novel drug targets
• Improve confidence in target-disease causality
• Increase the probability of success in the development of new therapies

Professor Sir Peter Donnelly, CEO and Co-Founder of Genomics, said: “Today represents more than a new office. It marks the next chapter in our commercial growth and our mission to harness the power of genetic insight to transform drug discovery and development, and healthcare. Combining our genomic capabilities with agentic AI on Mystra is a big step towards our goal of democratising access to genomic insights across the life sciences ecosystem – moving it from the realm of statistical genetics expertise towards a tool that can be queried by R&D scientists, development leads, and even management in pharma and biotech companies.”

Jodie Eastwood, CEO of the Knowledge Quarter, stated: "We are absolutely delighted to welcome Genomics to the Knowledge Quarter as a member alongside institutions such as the British Museum, Francis Crick Institute, Wellcome and University College London. Their new office strengthens the UK life sciences ecosystem and will facilitate the cross-sector collaborations needed for this next chapter of healthcare innovation. Their application of advanced AI to genomic data is exactly the type of forward-thinking science our innovation district is designed to foster."

As Genomics scales its work across life sciences, healthcare systems and population health, its presence in the Knowledge Quarter underscores our commitment to building long-term collaborations with our commercial partners, government and academia.

The company continues to expand collaborations with pharmaceutical and biotech partners globally, positioning the UK at the forefront of AI-powered drug discovery. 

For more information about Genomics, visit genomics.com

ENDS